These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 21366641)

  • 1. Architecture of the drug-drug interaction network.
    Hu TM; Hayton WL
    J Clin Pharm Ther; 2011 Apr; 36(2):135-43. PubMed ID: 21366641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signal detection in pharmacovigilance: empirical evaluation of data mining tools.
    Chan KA; Hauben M
    Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):597-9. PubMed ID: 16134080
    [No Abstract]   [Full Text] [Related]  

  • 3. [Importance of knowledge of information on adverse effects and interactions of drugs].
    Stanimirović V; Babić M; Cucak S; Nikolić D; Nikolić A
    Srp Arh Celok Lek; 2000; 128(3-4):135-9. PubMed ID: 10932625
    [No Abstract]   [Full Text] [Related]  

  • 4. Chem-tox informatics: data mining using a medicinal chemistry building block approach.
    Johnson DE; Blower PE; Myatt GJ; Wolfgang GH
    Curr Opin Drug Discov Devel; 2001 Jan; 4(1):92-101. PubMed ID: 11727328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Network analysis of adverse drug interactions.
    Takarabe M; Okuda S; Itoh M; Tokimatsu T; Goto S; Kanehisa M
    Genome Inform; 2008; 20():252-9. PubMed ID: 19425139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Unwanted drug interactions. Keeping up pharmacovigilance using databases].
    Schindler B
    Med Monatsschr Pharm; 2008 Apr; 31(4):155-6. PubMed ID: 18497254
    [No Abstract]   [Full Text] [Related]  

  • 7. Methods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD.
    Schuemie MJ
    Pharmacoepidemiol Drug Saf; 2011 Mar; 20(3):292-9. PubMed ID: 20945505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A potential competition bias in the detection of safety signals from spontaneous reporting databases.
    Pariente A; Didailler M; Avillach P; Miremont-Salamé G; Fourrier-Reglat A; Haramburu F; Moore N
    Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1166-71. PubMed ID: 20848561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical use and outcomes in children.
    Mullins CD
    Clin Ther; 2009 Feb; 31(2):420. PubMed ID: 19302914
    [No Abstract]   [Full Text] [Related]  

  • 10. Characterization and classification of adverse drug interactions.
    Takarabe M; Shigemizu D; Kotera M; Goto S; Kanehisa M
    Genome Inform; 2010 Jan; 22():167-75. PubMed ID: 20238427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug interactions in an intensive care unit].
    Nielsen EW; Dybwik K
    Tidsskr Nor Laegeforen; 2004 Nov; 124(22):2907-8. PubMed ID: 15550963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computer-aided prediction of receptor profile for drug-like compounds.
    Borodina Y; Filimonov D; Poroikov V
    SAR QSAR Environ Res; 2002; 13(3-4):433-43. PubMed ID: 12184385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EU-ADR healthcare database network vs. spontaneous reporting system database: preliminary comparison of signal detection.
    Trifirò G; Patadia V; Schuemie MJ; Coloma PM; Gini R; Herings R; Hippisley-Cox J; Mazzaglia G; Giaquinto C; Scotti L; Pedersen L; Avillach P; Sturkenboom MC; van der Lei J; Eu-Adr Group
    Stud Health Technol Inform; 2011; 166():25-30. PubMed ID: 21685607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor?
    Trifirò G; Pariente A; Coloma PM; Kors JA; Polimeni G; Miremont-Salamé G; Catania MA; Salvo F; David A; Moore N; Caputi AP; Sturkenboom M; Molokhia M; Hippisley-Cox J; Acedo CD; van der Lei J; Fourrier-Reglat A;
    Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1176-84. PubMed ID: 19757412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can F-MTI semantic-mined drug codes be used for adverse drug events detection when no CPOE is available?
    Merlin B; Chazard E; Pereira S; Serrot E; Sakji S; Beuscart R; Darmoni S
    Stud Health Technol Inform; 2010; 160(Pt 2):1025-9. PubMed ID: 20841839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-drug interaction programs in clinical practice.
    Pham PA
    Clin Pharmacol Ther; 2008 Mar; 83(3):396-8. PubMed ID: 18285786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Structuring drug-to-drug interaction knowledge based on formal representation].
    Okada M; Okada M
    Iyodenshi To Seitai Kogaku; 1985 Sep; 23(5):329-33. PubMed ID: 3841374
    [No Abstract]   [Full Text] [Related]  

  • 18. Mining pharmacovigilance data using Bayesian logistic regression with James-Stein type shrinkage estimation.
    An L; Fung KY; Krewski D
    J Biopharm Stat; 2010 Sep; 20(5):998-1012. PubMed ID: 20721787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WikiPharma - a freely available, easily accessible, interactive and comprehensive database for environmental effect data for pharmaceuticals.
    Molander L; Gerstrand M; Rudén C
    Regul Toxicol Pharmacol; 2009 Dec; 55(3):367-71. PubMed ID: 19720105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug interaction microcomputer software evaluation: Drug Therapy Screening System (DTSS).
    Poirier TI; Giudici RA
    Hosp Pharm; 1990 Aug; 25(8):738-41, 744. PubMed ID: 10170582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.